Supernus has boosted its position in central ... are for Parkinson's disease, while the third (Myobloc) is a botulinum toxin product for cervical dystonia and chronic sialorrhea.

Supernus Pharmaceuticals Background Information ... for the acute treatment of hypomobility in advanced Parkinson's disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical ...

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other cash-rich small cap stocks. Small-cap stocks in the US have been under ...

Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression. The stock was down 22% to $31.62 in ...